Amino Acid Transport Systems β and A in Fetal T Lymphocytes in Intrauterine Growth Restriction and With Tumor Necrosis Factor- α Treatment

CHIBUIKE G. IRULOH, STEPHEN W. D'SOUZA, WILLIAM D. FERGUSSON, PHILIP N. BAKER, COLIN P. SIBLEY, AND JOCELYN D. GLAZIER

Maternal and Fetal Health Research Group [C.G.I., S.W.D., P.N.B., C.P.S., J.D.G.], Regional Genetics Service and Academic Unit of Medical Genetics [W.D.F.], University of Manchester, St Mary's Hospital, Manchester M13 0JH, United Kingdom

ABSTRACT: Intrauterine growth restriction (IUGR) is associated with reduced activity of placental amino acid transport systems β and A. Whether this phenotype is maintained in fetal cells outside the placenta is unknown. In IUGR, cord blood tumor necrosis factor (TNF)- α concentrations are raised, potentially influencing amino acid transport in fetal cells. We used fetal T lymphocytes as a model to study systems β and A amino acid transporters in IUGR compared with normal pregnancy. We also studied the effect of TNF- α on amino acid transporter activity. In fetal lymphocytes from IUGR pregnancies, taurine transporter mRNA expression encoding system β transporter was reduced, but there was no change in system β activity. No significant differences were observed in system A mRNA expression (encoding SNAT1 and SNAT2) or system A activity between the two groups. After 24 or 48 h TNF- α treatment, fetal T lymphocytes from normal pregnancies showed no significant change in system A or system β activity, although cell viability was compromised. This study represents the first characterization of amino acid transport in a fetal cell outside the placenta in IUGR. We conclude that the reduced amino acid transporter activity found in placenta in IUGR is not a feature of all fetal cells. (Pediatr Res 65: 51-56, 2009)

Intrauterine growth restriction (IUGR) occurs when a fetus fails to achieve its expected growth potential and may complicate approximately 5% of pregnancies (1). The shortand long-term consequences include perinatal morbidity with an increased risk of a "cerebral insult" and neurodevelopmental impairments in later childhood (2). In IUGR, there is a reduction in cord plasma concentration of amino acids including essential amino acids (3,4), underscored by a reduced activity of certain amino acid transport systems in the syncytiotrophoblast of human placenta (5).

Amino acid transfer across the placenta is mediated by transporters in the maternal-facing microvillous plasma membrane (MVM) and fetal-facing basal plasma membrane (BM) of the syncytiotrophoblast (6). Plasma amino acid concentrations are higher in the fetus than in the mother, in keeping with active transport systems in MVM and BM. In IUGR, the activities of a range of amino acid transporters in MVM and BM are reduced (5). These include system A transporter in

Supported, in part, by a Wellcome Trust project grant (071224/Z/03/Z).

MVM (7–9), system L transporter in MVM and BM (10), system y⁺L transporter in BM (10), and system β transporter in MVM (11). Furthermore, stable isotope studies have shown that placental supply of leucine and phenylalanine exceeds fetal demand for protein synthesis by only a small amount suggesting a narrow safety margin for placental transfer of these essential amino acids (12). Thus, reduced amino acid placental transfer in IUGR has the potential to directly limit fetal growth (5,13).

The basis for this decreased placental amino acid transport activity is not clearly understood. It may have a genetic basis or may be secondary to an alteration in the metabolic and/or endocrine milieu of the mother or the fetus. If there is a genetic element to the decreased placental amino acid transport in IUGR, then a similar decrease could be proposed in other fetal cells, reducing the capacity for cell division and subsequent growth. Metabolic or endocrine perturbations, such as the reduced amino acid concentrations in fetal plasma in IUGR, could result in adaptive up-regulation of transporters in fetal cells (14). Furthermore, in IUGR the increase in circulating plasma tumor necrosis factor (TNF)- α concentration (15) may influence amino acid transporter activity (16). These situations raise the possibility that changes in amino acid transport could occur in fetal cells outside the placenta, thereby contributing to the pathophysiology of IUGR. This concept is also relevant to understanding the sequelae after such an infant is born, because the potential for catch-up growth and development postnatally may be influenced by alterations that have taken place to these amino acid transporters in utero.

We have recently developed a technique to isolate pure, viable fetal T lymphocytes from cord blood as an easily accessible fetal cell type, and have demonstrated system β -mediated taurine transport by these cells (17). Our observations here also indicate that these cells express the ubiquitous amino acid transporter system A, which transports neutral amino acids with short or linear side chains, including alanine, serine, and glycine (18). System A has the unique ability to transport *N*-methylated amino acid α -(methylamino)isobu-

Abbreviations: AGA, appropriate for gestational age; BM, basal plasma membrane; MeAIB, α -(methylamino)isobutyric acid; MVM, microvillous plasma membrane; SNAT, sodium-coupled neutral amino acid transporter; TAUT, taurine transporter

Received May 14, 2008; accepted August 6, 2008.

Correspondence: Jocelyn D. Glazier, Ph.D., Maternal and Fetal Health Research Group, University of Manchester, St Mary's Hospital, Hathersage Road, Manchester M13 0JH, UK; e-mail: j.glazier@manchester.ac.uk

tyric acid (MeAIB) (18), a substrate widely used to study system A activity in placenta. System A activity is mediated by three highly homologous isoforms of the sodium-coupled neutral amino acid transporter (SNAT) family, namely SNAT1, SNAT2, and SNAT4, which are encoded by the genes SLC38A1, SLC38A2, and SLC38A4, respectively (18).

We hypothesized that the activity and expression of amino acid transporter systems in fetal cells outside the placenta would be reduced in IUGR compared with normal pregnancies. The aims of this study were first, to examine mRNA expression of taurine transporter (TAUT) and SNAT isoforms in fetal lymphocytes, comparing IUGR with appropriate-forgestational age (AGA) infants. Second, to determine whether the transport activity of systems β and A was altered in fetal T lymphocytes obtained from cord blood of infants born at term with IUGR as compared with that in lymphocytes from AGA infants. Third, to investigate the cytokine-mediated effects of TNF- α on system β and system A transporter activity in fetal T lymphocytes from normal pregnancy.

MATERIALS AND METHODS

Tissue acquisition. All cord blood or placental tissue samples were obtained with written informed consent as approved by the Central Manchester Local Research Ethics Committee. Placentas were obtained after vaginal delivery or cesarean section from normal pregnancies (AGA) or IUGR pregnancies at term (37–42 wk). IUGR was defined as an individualized birth ratio (IBR) <6th centile, with or without a reduction in growth velocity on serial growth scans or changes in umbilical artery blood flow as determined by Doppler studies. By using IBR, birthweight for gestational age was corrected for the confounding variables of maternal height and weight, ethnic origin, parity, and infant sex (19). Babies with chromosomal and congenital anomalies and pregnancies complicated by other pathologies were excluded.

Cord blood from the chorionic vessels (10–60 mL) was obtained within 15 min of delivery of the placenta as 10 mL aliquots using a 21-gauge needle and placed in 25 mL sterile universal bottles with 400 units sodium heparin without preservative (CP Pharmaceuticals, Wrexham, UK).

Isolation of fetal T lymphocytes. Pure and viable fetal T lymphocytes were obtained from cord blood as described previously (17). Briefly, fetal T lymphocytes were isolated by two rounds of density gradient centrifugation followed by immunomagnetic bead depletion of contaminating cells. The purity of the T lymphocyte isolates was determined by flow cytometry using CD3 as a T-cell marker (17). T lymphocyte viability was assessed by 0.1% trypan blue exclusion (17).

System β activity. After isolation, fetal T lymphocytes were suspended in Tyrode's buffer (in mM: 135 NaCl, 5 KCl, 1.8 CaCl₂, 1 MgCl₂·6H₂O, 10 HEPES, and 5.6 glucose, pH 7.4) containing 0.1% bovine serum albumin (BSA). System β activity, taken as the uptake of 0.2 μ M ³H-taurine over 15 min, was measured as described previously (17) using 30 μ L cells (3–5 × 10⁶ cells). The cells were preincubated in Tyrode's buffer for 30 min before amino acid uptake, to reduce intracellular concentration of amino acids and avoid trans-inhibition.

System A activity. The procedure for the measurement of system A activity was similar to that for system β (17), measured as the uptake of ¹⁴C-MeAIB. Thirty microliter cells (3–5 × 10⁶ cells) were mixed with 20 μ L Tyrode's/ 0.1% BSA containing 500 μ M ¹⁴C-MeAIB to give an incubation volume of 50 μ L containing 200 μ M ¹⁴C-MeAIB.

TAUT mRNA expression. Expression of TAUT mRNA in fetal T lymphocytes was quantified by real-time quantitative PCR (qPCR) using intercalation of SYBR Green with normalization to term placenta as internal calibrator as described previously (17). Amplification capacity was confirmed in all samples using β -actin primers, as detailed previously (17).

SNAT mRNA expression. SLC38A1 (SNAT1), SLC38A2 (SNAT2), and SLC38A4 (SNAT4) mRNA expression in fetal T lymphocytes was quantified as described above using primers that had been previously validated and confirmed to be specific for each of the SNAT isoforms (20). Electrophoresis of all qPCR products on agarose gel (2%) in the presence of ethidium bromide (0.5 µg/mL) was undertaken to confirm primer specificity, inferred by the visualization of a single amplicon of the predicted size.

TNF-α treatment of *I lymphocytes*. Isolated T lymphocytes from normal, term pregnancies were suspended in culture media (RPMI 1640 Glutamax with 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin: all from Invitrogen, Paisley, Scotland). Viability and count was determined by trypan blue exclusion and the cells were then split into different flasks at a concentration of $0.5-1.0 \times 10^6$ cells/mL ($5-6 \times 10^6$ cells/flask). The cells were cultured with 0, 20, and 50 ng/mL recombinant human TNF-*α* (Invitrogen) at 37°C in a humidified atmosphere with 5% CO₂ for 24 or 48 h, respectively. After culture, the cells were washed with phosphate-buffered saline/0.1% BSA and suspended in Tyrode's/0.1% BSA. The viability and number of cells were determined and uptakes performed for systems *β* and A (10 min incubation) as detailed above.

Statistical analysis. Statistical analyses were performed using Prism version 4.01 (GraphPad Software, San Antonio, CA). The clinical characteristics, blood volume, number of T lymphocytes recovered, and cell viability of term AGA and IUGR babies are presented as mean \pm SEM. For the time courses, ³H-taurine uptake by system β and ¹⁴C-MeAIB uptake by system A, is presented as mean \pm SEM. Linear regression analysis was applied to determine linearity of uptake over 15 min. Relative mRNA expression is presented as median, 25th and 75th centile and range was analyzed with the Mann–Whitney test. For TNF- α treatment of cells, T-lymphocyte viability and uptake of radiolabeled substrates between different treatment groups with time was analyzed by two-way repeated-measures analysis of variance (ANOVA) with Bonferroni's multiple comparison post-test, where there was a significant difference. For all analyses, n = number of placentas with a value of p < 0.05 considered significant.

RESULTS

Clinical characteristics of AGA and IUGR babies. There was a significant difference in the birthweight of AGA and IUGR babies (Table 1). There were no significant differences in the gestational age of the pregnancies, the sex, or the mode of delivery of the babies. Seven of the 11 AGA babies and seven of the eight IUGR babies were born to Caucasian parents.

Characteristics of T-lymphocyte isolates. The volume of cord blood that could be harvested from IUGR babies was significantly less than that from AGA babies (Table 2). However, this did not compromise the number of T lymphocytes isolated per unit volume of cord blood, which was comparable

 Table 1. Clinical characteristics of AGA and IUGR groups used to isolate fetal T lymphocytes in this study

	AGA $(n = 11)$	IUGR $(n = 8)$
Gestation (d)	274 ± 3	270 ± 4
Birthweight (g)	3579 ± 152	2165 ± 179*
Sex	M = 7; F = 4	M = 4; F = 4
Mode of delivery	VD = 9; CS = 2	VD = 4; CS = 3; Ve = 1

Data are presented as mean \pm SEM.

* p < 0.001 vs AGA (two-tailed t test).

M, male; F, female; VD, vaginal delivery; CS, cesarean section; Ve, ventouse delivery.

 Table 2. Umbilical cord blood volume harvested and number and viability of T lymphocytes isolated from the umbilical cord blood of AGA and IUGR babies

	AGA*	IUGR
Blood volume harvested (mL)	$38.9 \pm 1.8 \ (n = 27)$	$31.0 \pm 3.4 \ (n = 9)$ †
No. T lymphocytes isolated	$7.6 \pm 0.7 \ (n = 26)$	$5.8 \pm 1.2 \ (n = 9)$
$(10^{6}/10 \text{ mL cord blood})$		
Cell viability (%)	97.8 ± 0.7 ($n = 24$)	$99.2 \pm 0.4 \ (n = 9)$

Data are presented as mean \pm SEM.

* The number of AGA samples is different between variables measured because of incomplete data.

 $\dagger p < 0.05 vs$ AGA (two-tailed Student's t test).

between the two groups with good preservation of cell viability in both groups (Table 2). It is noteworthy that in several placentas from IUGR pregnancies, the volume of cord blood that could be harvested was below the threshold required for the successful execution of the isolation procedure, limiting the number of samples that could be analyzed.

System β . Figure 1 confirms TAUT mRNA expression in fetal T lymphocytes from both AGA and IUGR groups. Relative TAUT mRNA expression was significantly lower in IUGR T lymphocytes compared with AGA lymphocytes (Fig. 1B). The identity of the TAUT mRNA was confirmed by the generation of a single amplicon of appropriate size (117 bp) in all samples which co-migrated with placenta as positive control. The lack of difference in β -actin mRNA expression between lymphocytes in each group (Fig. 1A) confirms com-

parable cDNA integrity in both groups. System β activity, measured as ³H-taurine uptake over 5–15 min, was timedependent and linear and not different (two-way ANOVA) between groups (Fig. 1C).

System A. Gene expression studies of system A subtypes in fetal T lymphocytes demonstrated expression of SLC38A1 (SNAT1) and SLC38A2 (SNAT2) mRNA, whereas SLC38A4 (SNAT4) mRNA was undetectable (no cycle threshold value recorded) despite clear visualization of SLC38A4 amplicon in the positive controls (Fig. 2). This observation was consistent between the two groups of fetal T lymphocytes (Fig. 2) and so mRNA expression of SLC38A1 and SLC38A2 only was compared (Fig. 3). SLC38A1 and SLC38A2 amplification products detected in T lymphocytes from both groups were of the predicted size and co-migrated with positive controls (Fig.



Figure 1. Expression of (A) β -actin and (B) TAUT mRNA in AGA (n = 5) and IUGR (n = 6) fetal T lymphocytes; (C) ³H-taurine uptake by fetal T lymphocytes from AGA (\blacksquare , n = 6; $r^2 = 0.995$, p < 0.05, solid line) and IUGR (\triangle , n = 6; $r^2 = 0.998$, p < 0.05, dashed line) babies. Data in Figure 1A and B are presented as box and whiskers (box extends from the 25th to the 75th centile, whiskers represent range and horizontal line is median). *p < 0.01 vs IUGR, two-tailed Mann–Whitney test. In Figure 1C, the linear regression plot is shown with data presented as mean ± SEM.



Figure 2. Gel electrophoresis of qPCR products for (A) SLC38A1 (SNAT1), (B) SLC38A2 (SNAT2), and (C) SLC38A4 (SNAT 4) in standard (S1 = 100 ng), AGA lymphocyte (L1, L2), IUGR lymphocyte (R1, R2), placenta (Pl), liver (Li), and negative controls (lanes NTC, NRT, and H). The products were of the expected size of 187, 141, and 152 bp, respectively. NTC = no template control; NRT = no reverse transcriptase; $H = H_2O$. 100La = 100 bp ladder.



Figure 3. Relative mRNA expression of (A) SNAT 1 and (B) SNAT 2 in AGA (n = 5) and IUGR (n = 6) fetal T lymphocytes; (C) ¹⁴C-MeAIB uptake by fetal T lymphocytes from AGA (\blacksquare , n = 6; $r^2 = 0.987$, p = 0.07, solid line) and IUGR (\triangle , n = 6; $r^2 = 0.999$, p = 0.02, dashed line) babies. Data in Figure 3A and B are presented as box and whiskers (box extends from the 25th to the 75th centile, whiskers represent range and horizontal line is median). SNAT 1 and SNAT 2 mRNA expression was comparable between the groups. In Figure 3C, the linear regression plot is shown with data presented as mean \pm SEM.

2). There was no difference in SLC38A1 and SLC38A2 mRNA expression between AGA and IUGR T lymphocytes (Figs. 3A and B). System A activity, as represented by uptake of 200 μ M ¹⁴C-MeAIB over 5–15 min, was time-dependent and linear and was not different (two-way ANOVA) between AGA and IUGR T lymphocytes (Fig. 3C).

TNF-α treatment of fetal T lymphocytes. Fetal T lymphocyte cell viability was unaltered after 24 h incubation with either 20 or 50 ng/mL TNF-α. However, after 48 h of culture with 50 ng/mL TNF-α, T-lymphocyte cell viability was significantly (p < 0.05) reduced (89.5 ± 3.1%; mean ± SEM) compared with control cells without TNF-α treatment (97.7 ± 0.8%) as shown in Figure 4. After 24 and 48 h culture, TNF-α did not affect the activity of either system β or system A in fetal T lymphocytes (Fig. 5). For all the treatment groups, system A activity was significantly raised after 48 h of culture (p < 0.05; two-way repeated measures ANOVA with Bonferroni's multiple comparison test).



Figure 4. Fetal T-lymphocyte viability after 24 and 48 h culture without (control; \blacksquare) or with 20 ng/mL (\square) or 50 ng/mL \blacksquare TNF- α . Cell viability was significantly reduced by 50 ng/mL TNF- α after 48 h (two-way repeated-measures ANOVA with Bonferroni's post-test). Data are presented as mean + SEM, n = 6; *p < 0.05 control vs 50 ng/mL TNF- α .



Figure 5. Uptake of (A) ³H-taurine by system β and (B) ¹⁴C-MeAIB by system A in fetal T lymphocytes after 24 and 48 h culture without (control;) or with 20 ng/mL () or 50 ng/mL TNF- α . TNF- α had no effect on either taurine or MeAIB uptake. Data are presented as mean + SEM, n = 5 for both.

DISCUSSION

In this study, we have examined whether the altered amino acid transport function observed in the placentas of IUGR pregnancies (5,13) is also reflected in other fetal cells outside the placenta. To address this issue we have focused on two amino acid transport systems, system β and system A, the activities of which are reduced in the placentas of IUGR pregnancies (8,9,11). We elected to use fetal T lymphocytes as a fetal cell model as these cells are readily accessible, and can be isolated to a high degree of purity, constituting a wellcharacterized fetal cell population in which transport function can be examined (17).

The IUGR babies in this study were delivered at term, there being no difference in gestational age compared with the AGA babies, suggesting that these were mild to moderate IUGR cases that did not necessitate preterm clinical intervention. However, evidence of growth restriction was supported by the significantly lower birthweight of this group. Although several severely growth restricted babies were recruited to the study, minimal cord blood could be obtained at birth or the T lymphocytes isolated were heavily contaminated with red blood cells precluding their use, thereby limiting the number of samples available in this study. We speculate that this contamination most likely arises from nucleated red cells, as the nucleated red cell count in cord blood is increased in pregnancies complicated by IUGR (21). Although a lower blood volume was harvested from the placenta of IUGR pregnancies, there was comparability in the number of cells isolated per unit volume, suggesting cell recovery was equally efficient in both groups. Despite the reduced expression of TAUT mRNA observed in IUGR T lymphocytes, system β activity in these cells was unaltered, suggesting discordance between TAUT mRNA expression and system β activity. This is interesting in the light of other studies reporting divergence between expression of TAUT and system β activity in placenta (22). The reduced abundance of TAUT mRNA in IUGR T lymphocytes was not mirrored by a change in SLC38A1, SLC38A2, or β -actin mRNA levels, suggesting this response was TAUT-specific and not reflective of a generalized downregulation in cellular transcription in the IUGR group. We were not able to measure the Na⁺-dependent component of ³H-taurine as an index of system β activity in this study (or for system A) because of the constraints in the number of cells recovered (~18 \times 10⁶ cells in IUGR group; Table 2) and the requirement for $3-5 \times 10^6$ cells per activity measurement (17).

In this study, we have confirmed that system A is expressed and functionally active in fetal T lymphocytes, as evidenced by the uptake of radiolabeled MeAIB, considered a paradigm substrate for this transport system (18). This would be anticipated based on the ubiquitous expression of system A and its key role in the cellular provision of neutral amino acids (18). System A activity demonstrated here is likely to be by SNAT1- and SNAT2-mediated activity, based on the demonstration of mRNA expression for both these isoforms in this cell type. Although SLC38A2 (SNAT2) mRNA expression has a broad tissue distribution with ubiquitous expression, SLC38A1 (SNAT1) exhibits a more restricted expression (23,24), leading to the proposal that SNAT2 is likely to represent the classic system A transporter. Several tissues, including placenta, co-express both SNAT1 and SNAT2 transcripts (20,24,25), as shown here in fetal T lymphocytes. The lack of SNAT4 mRNA in fetal T lymphocytes is interesting as other fetal cell types within the human placenta, notably syncytiotrophoblast and fetal capillary endothelium, express SNAT4 (20). This study, therefore, highlights the cell-specific nature of fetal SNAT4 expression and suggests that SNAT4mediated amino acid transport subserves a cell-specific role in amino acid provision. Rodent placenta also expresses SNAT4 (25), implicating an important role for SNAT4 in placental function, perhaps related to fetal growth and development (20).

The observations made here, that system β or system A amino acid transporter activity in fetal T lymphocytes is not altered in IUGR, as compared with that in AGA infants, contrasts with previous placental studies that have shown a reduction in the activity of these transporters in the syncytiotrophoblast plasma membranes in IUGR pregnancy (5,13). The studies on placenta showing differences in amino acid transporter activity include term IUGR clinical groups similar to those studied here (7) and more severely affected groups (8). Other studies have further suggested that the reduction in system A activity plays a causative role in inducing IUGR (26-28), compatible with the observation that the magnitude of diminution in system A activity in MVM relates to the severity of IUGR (8). Our observation that neither system β nor system A activity is altered in fetal T lymphocytes implies that the aberrant functional phenotype of syncytiotrophoblast in IUGR pregnancy (5,13) is not manifested in all fetal cells. A reduced amino acid transporter activity in fetal T lymphocytes might influence their proliferation and differentiation impacting on neonatal host-defense mechanisms (29).

A regulatory feature of both system β and system A is the ability to undergo adaptive regulation, being up-regulated by extracellular substrate starvation. This is pertinent with regard to IUGR as the concentration of some essential amino acids in cord plasma is reduced (3,4). Our observations, as evidenced by the lack of change in both transporter activities in fetal T lymphocytes from IUGR pregnancies compared with the AGA group, argue against these cells having evoked an adaptive regulation response in relation to these transport mechanisms. Consistent with this notion, there was no evidence in fetal T lymphocytes of up-regulated TAUT and SLC38A2 gene transcription associated with adaptive regulation (14).

Our studies on the treatment of fetal T lymphocytes with TNF- α have shown that this cytokine had no effect on the activity of amino acid transport systems β and A, despite a small reduction in cell viability after 48 h with 50 ng/mL TNF- α . Previous studies suggest that treatment with TNF- α may cause DNA damage and an increase in the percentage of apoptotic cells at concentrations greater than 10 ng/mL (30). The ability of TNF- α to stimulate amino acid transport is restricted to certain cell types (31). We cannot exclude the possibility that the effects of TNF- α were acute and transitory. However, system A transporter activity appeared to increase after the lymphocytes were incubated for 48 h, despite a reduction in viability after 50 ng/mL TNF- α treatment. It is

not clear what the stimulus for system A amino acid transport might be as the increase in ¹⁴C-MeAIB took place irrespective of TNF- α treatment. Adaptive up-regulation of this amino acid transporter is a possibility (14), arising from the cellular consumption of amino acids.

To summarize, this is the first study to investigate amino acid transporter activity in a readily available, nonpassaged cell type outside the placenta in IUGR. The reduction in TAUT mRNA in fetal T lymphocytes from IUGR babies is at variance with a lack of change in system β activity, although the relationship between mRNA expression, protein expression, and amino acid transporter activity is complex with evidence for a lack of direct correspondence between these variables (20,22). The presence of SLC38A1 and SLC38A2 transcripts in fetal T lymphocytes and the absence of SLC38A4 transcripts suggest that SNAT4 is not involved in fetal T lymphocyte metabolism, and that system A activity in these cells is mediated by SNAT1 and SNAT2 subtypes. The activity of system β and system A in fetal T lymphocytes from AGA pregnancies was not affected by exposure to TNF- α over a 48-h timeframe, although cellular responsiveness to TNF- α was inferred by the observation of a significant reduction in viability at the highest dose applied. We conclude that the impaired transporter phenotype described in the syncytiotrophoblast (5,13) is not present in fetal T lymphocytes, and further that there is not a unified down-regulation of amino acid transporter activity in all fetal cells from IUGR pregnancy.

Acknowledgments. We thank the midwives and medical staff at St. Mary's Hospital, Manchester, for their help in obtaining placentas.

REFERENCES

- 1. Chiswick ML 1985 Intrauterine growth retardation. BMJ (Clin Res Ed) 291: 845-848
- Pryor J 1997 The identification and long term effects of fetal growth restriction. Br J Obstet Gynaecol 104:1116–1122
- Economides DL, Nicoliades KH, Gahl WA, Bernardini I, Evans MI 1989 Plasma amino acids in appropriate- and small-for-gestational-age fetuses. Am J Obstet Gynecol 161:1219–1227
- Cetin I, Ronzoni S, Marconi AM, Perugino G, Corbetta C, Battaglia FC, Pardi G 1996 Maternal concentrations and fetal-maternal concentration differences of plasma amino acids in normal and intrauterine growth-restricted pregnancies. Am J Obstet Gynecol 174:1575–1583
- Jansson T, Powell TL 2007 Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches. Clin Sci 113:1–13
- Jansson T 2001 Amino acid transporters in human placenta. Pediatr Res 49:141–147
 Mahendran D, Donnai P, Glazier JD, D'Souza SW, Boyd RD, Sibley CP 1993 Amino acid (system A) transporter activity in microvillous membrane vesicles from placentas of appropriate and small for gestational age babies. Pediatr Res 34:661–665
- Glazier JD, Cetin I, Perugino G, Ronzoni S, Grey AM, Mahendran D, Pardi G, Sibley CP 1997 Association between the activity of the system A amino acid transporter in the microvillous plasma membrane of the human placenta and the severity of fetal compromise in intrauterine growth restriction. Pediatr Res 42:514–519
- Jansson T, Ylvén K, Wennergren M, Powell TL 2002 Glucose transport and system A activity in syncytiotrophoblast microvillous and basal membranes in intrauterine growth restriction. Placenta 23:386–391
- Jansson T, Scholtbach V, Powell TL 1998 Placental transport of leucine and lysine are reduced in intrauterine growth restriction. Pediatr Res 44:532–537
- Norberg S, Powell TL, Jansson T 1998 Intrauterine growth restriction is associated with reduced activity of placental taurine transporters. Pediatr Res 44:233–238
- Chien PF, Smith K, Watt PW, Scrimgeour CM, Taylor DJ, Rennie MJ 1993 Protein turnover in the human fetus studied at term using stable isotope tracer amino acids. Am J Physiol 265:E31–E35
- Sibley CP, Turner MA, Cetin I, Ayuk P, Boyd CA, D'Souza SW, Glazier JD, Greenwood SL, Jansson T, Powell T 2005 Placental phenotypes of intrauterine growth. Pediatr Res 58:827–832
- Christie GR, Hyde R, Hundal HS 2001 Regulation of amino acid transporters by amino acid availability. Curr Opin Clin Nutr Metab Care 4:425–431

- Bartha JL, Romero-Carmona R, Comino-Delgado R 2003 Inflammatory cytokines in intrauterine growth retardation. Acta Obstet Gynecol Scand 82:1099–1102
- Kang YS, Ohtsuki S, Takanaga H, Toni M, Hosoya K, Terasaki T 2002 Regulation of taurine transport at the blood–brain barrier by tumor necrosis factor-alpha, taurine and hypertonicity. J Neurochem 83:1188–1195
- Iruloh CG, D'Souza SW, Speake PF, Crocker I, Fergusson W, Baker PN, Sibley CP, Glazier JD 2007 Taurine transporter in fetal T lymphocytes and platelets: differential expression and functional activity. Am J Physiol Cell Physiol 292:C332–C341
- Mackenzie B, Erickson JD 2004 Sodium-coupled neutral amino acid (System N/A) transporters of the SLC38 gene family. Pflugers Arch 447:784–785
- Wilcox MA, Johnson IR, Maynard PV, Smith SJ, Chilvers CE 1993 The individualised birthweight ratio: a more logical outcome measure of pregnancy than birthweight alone. Br J Obstet Gynaecol 100:342–347
- Desforges M, Lacey HA, Glazier JD, Greenwood SL, Mynett KJ, Speake PF, Sibley CP 2006 SNAT4 isoform of system A amino acid transporter is expressed in human placenta. Am J Physiol Cell Physiol 290:C305–C312
- Vatansever U, Acunas B, Demir M, Karasalihoglu S, Ekuklu G, Ener S, Pala O 2002 Nucleated red blood cell counts and erythropoietin levels in high-risk neonates. Pediatr Int 44:590–595
- Roos S, Powell TL, Jansson T 2004 Human placental taurine transporter in uncomplicated and IUGR pregnancies: cellular localisation, protein expression and regulation. Am J Physiol Regul Integr Comp Physiol 287:R886–R893

- Hatanaka T, Huang W, Wang H, Sugawara M, Prasad PD, Leibach FH, Ganapathy V 2000 Primary structure, functional characteristics and tissue expression pattern of human ATA2, a subtype of amino acid transport system A. Biochim Biophys Acta 1467:1–6
- Wang H, Huang W, Sugawara M, Devoe LD, Leibach FH, Prasad PD, Ganapathy V 2000 Cloning and functional expression of ATA1, a subtype of amino acid transporter A, from human placenta. Biochem Biophys Res Commun 273:1175–1179
- Novak D, Lehman M, Bernstein H, Beveridge M, Cramer S 2006 SNAT expression in rat placenta. Placenta 27:510–516
- Cramer S, Beveridge M, Kilberg M, Novak D 2002 Physiological importance of system A-mediated amino acid transport to fetal rat development. Am J Physiol Cell Physiol 282:C153–C160
- Jansson N, Pettersson J, Haafiz A, Ericsson A, Palmberg I, Tranberg M, Ganapathy V, Powell TL, Jansson T 2006 Down regulation of placental transport of amino acids precedes the development of intrauterine growth restriction. J Physiol 576:935–946
- Constância M, Hemberger M, Hughes J, Dean W, Ferguson-Smith A, Fundele R, Stewart F, Kelsey G, Fowden A, Sibley C, Reik W 2002 Placental-specific IGF-II is a major modulator of placental and fetal growth. Nature 417:945–948
- Xanthou M 1985 Immunological deficiencies in small-for-dates neonates. Acta Paediatr Scand Suppl 319:143–149
- Rangamani P, Sirovich L 2007 Survival and apoptotic pathways initiated by TNF-alpha: modeling and predictions. Biotechnol Bioeng 97:1216–1229
- Mochizuki T, Satsu H, Shimizu M 2002 Tumor necrosis factor-alpha stimulates taurine uptake and transporter gene expression in human intestinal CaCo-2 cells. FEBS Lett 517:92–96